Scope, Claims, and US Patent Landscape for Drug Patent 10,344,765
What does US Patent 10,344,765 claim at the product level?
US Patent 10,344,765 claims an aqueous pharmaceutical formulation of AMG 416 hydrochloride with a defined acidic pH window and, in dependent claims, defined buffer type, API concentration ranges, tonicity adjustment, and stability thresholds.
Claim set coverage (independent and dependent)
Independent claim
- Claim 1: Aqueous solution containing AMG 416 hydrochloride with formulation pH 2.0 to 5.0.
Dependent claims narrow the same formulation concept
- pH ranges
- Claim 2: pH 2.5 to 4.5
- Claim 3: pH 2.5 to 4.0
- Claim 4: pH 3.0 to 3.5
- Buffer and buffer identity
- Claim 5: pH maintained by a pharmaceutically acceptable buffer
- Claim 6: buffer is succinate
- API concentration ranges
- Claim 7: 0.1 mg/mL to 20 mg/mL
- Claim 8: 1 mg/mL to 15 mg/mL
- Claim 9: 2.5 mg/mL to 10 mg/mL
- Tonicity control
- Claim 10: further comprising a pharmaceutically acceptable tonicity modifier
- Claim 11: tonicity modifier amount makes formulation approximately isotonic
- Claim 12: tonicity modifier is NaCl
- Stability requirements
- Claim 13: < 10% degradation after storage 2-8°C for 2 years
- Claim 14: < 10% degradation after storage room temperature for 2 years
- Tight “preferred” combination
- Claim 15: AMG 416 hydrochloride 2 mg/mL to 20 mg/mL, succinate buffer maintaining pH about 3.0 to 3.5, plus NaCl concentration to make formulation approximately isotonic
Practical scope: what is captured and what is not
Captured
- Any aqueous AMG 416 hydrochloride formulation that lands inside pH 2.0 to 5.0 (Claim 1), including acidic sub-ranges (Claims 2-4).
- Formulations that use succinate to achieve and maintain the pH target (Claims 5-6; also Claim 15).
- Formulations with API concentration in any of the claimed tiers (Claims 7-9), including a combined tight scheme (Claim 15).
- Formulations with tonicity adjustment to approximately isotonic, including when the modifier is NaCl (Claims 10-12, 15).
- Formulations that meet the stated two-year degradation thresholds at both cold and room temperature (Claims 13-14).
Not captured (by claim language)
- Non-aqueous formulations or formulations with pH outside the windows.
- Formulations that use a buffer system not meeting the dependent-claim buffer identity (succinate) when relying on Claims 5-6 or Claim 15.
- Formulations that fail to meet the <10% degradation conditions when asserting Claims 13-14.
- Formulations that adjust tonicity but do not reach “approximately isotonic,” or use a tonicity modifier other than NaCl where the claim depends on NaCl (Claims 12 and 15).
What is the claim structure for freedom-to-operate (FTO) and design-around?
The claims are built to force compliance across four technical “knobs”: pH, buffer chemistry, API concentration, and tonicity + stability performance. This matters because an accused product can avoid infringement by changing any one required element of the asserted claim.
Infringement map by claim “knob”
| Knob |
Claim(s) that lock it |
How it constrains scope |
| pH window |
Claim 1-4, 15 |
Primary gate; every version must satisfy pH limits for independent claim coverage |
| Buffer system |
Claim 5-6, 15 |
Succinate becomes material when asserting dependent claims |
| Concentration |
Claim 7-9, 15 |
Narrowing tiers provide additional claim hooks if the product dose strength falls into the ranges |
| Tonicity modifier |
Claim 10-12, 15 |
NaCl identity is required in the most specific dependent hook |
| Stability criteria |
Claim 13-14 |
Product must perform over defined storage conditions to meet those dependent claim limitations |
Claim hierarchy implications for litigation posture
- Claim 1 is broad on pH and formulation type (aqueous + AMG 416 hydrochloride). If the product fits, it creates a baseline exposure regardless of buffer identity and tonicity modifier.
- Claims 2-4 reduce pH to narrower sub-ranges, supporting infringement theories tailored to the actual formulation pH.
- Claims 5-6 and 15 add “buffer is succinate,” enabling a second set of arguments if Claim 1 is disputed on pH boundary or if multiple products exist.
- Claims 7-9 and 15 create concentration-specific hooks, which matters for combination products and marketed strengths.
- Claims 13-14 shift the dispute to stability data. Where stability testing is hard to compare cross-product, this can become a key evidentiary battleground.
Where does this formulation sit in a typical AMG 416 (KRAS G12C pathway) landscape?
AMG 416 hydrochloride is a known small-molecule drug candidate/class in KRAS G12C targeted therapy portfolios. Formulation patents for such drugs often cluster around:
- Acidic pH solubilization windows
- Specific buffer systems to maintain pH under shelf-life conditions
- Isotonic tonicity adjustment
- Stability claims tied to defined storage conditions
Within this patent, the claim language signals that the key technical contribution asserted is controlling chemical degradation by controlling pH and buffer composition in aqueous solution, with additional manufacturability/compatibility via tonicity and isotonicity.
How broad is the pH scope in Claim 1 versus narrower dependent claims?
Claim 1: pH 2.0 to 5.0
- This covers a wide acidic range that overlaps many solubilization regimes for hydrochloride salts.
Dependent narrowing
- Claim 2: pH 2.5 to 4.5
- Claim 3: pH 2.5 to 4.0
- Claim 4: pH 3.0 to 3.5
Interpretation for enforcement
- If a marketed product uses a pH such as 3.2, it can implicate Claims 1, 2, 3, and 4 simultaneously.
- If a product uses pH 4.2, it can still implicate Claims 1 and 2, but avoid Claim 3 and Claim 4 depending on boundary handling.
- If a product uses pH 2.3, it implicates Claim 1 and Claim 2 but can avoid Claim 3 and Claim 4.
What does the “succinate buffer” language do to design-around?
Succinate is both:
- a pH maintenance mechanism (Claim 5), and
- an identity restriction (Claim 6, and Claim 15).
For an FTO analysis, the critical point is that succinate is not required for Claim 1. That means:
- Changing buffer away from succinate may avoid dependent claim coverage but may not avoid independent claim exposure if the product still uses aqueous AMG 416 hydrochloride in pH 2.0 to 5.0.
- Succinate matters mainly to avoid dependent claim assertions tied to succinate identity.
How do API concentration tiers affect freedom-to-operate?
Because the dependent claims add concentration brackets, the exposure can be product-strength specific.
- Claim 7: 0.1 to 20 mg/mL (broad; likely covers most plausible strengths)
- Claim 8: 1 to 15 mg/mL (mid-tier)
- Claim 9: 2.5 to 10 mg/mL (more targeted)
- Claim 15: 2 to 20 mg/mL (tighter but overlaps Claim 7)
If the marketed product concentration falls in multiple tiers, the patent supports multiple infringement counts.
How do tonicity and NaCl identity function in the landscape?
- Claim 10-11: tonicity modifier is present at an amount to make the formulation approximately isotonic.
- Claim 12: the tonicity modifier is NaCl.
- Claim 15: adds NaCl concentration plus succinate buffer and pH 3.0 to 3.5.
This is a design-around lever, but it is not the main gate if Claim 1 is asserted. In practice:
- Avoiding NaCl may reduce risk of dependent claim coverage (Claims 12 and 15), but not avoid Claim 1 when pH is still within 2.0 to 5.0.
What do the stability claims require in practice?
The dependent stability provisions are:
- Claim 13: <10% degradation after 2-8°C for 2 years
- Claim 14: <10% degradation after room temperature for 2 years
These are not limited by buffer or tonicity language within the dependent claim text. They function as performance requirements attached to the formulation of Claim 1.
From an enforceability standpoint, stability claims shift analysis to:
- measured degradation endpoints,
- test conditions,
- analytical method comparability,
- and whether “degradation” is defined consistently in the patent specification.
Most likely “asserted-claim pathway” scenarios
Given typical litigation strategies for formulation patents:
- Primary attack via Claim 1 (pH 2.0 to 5.0) if the product pH sits inside the window.
- Secondary reliance on dependent pH narrowing (Claims 2-4) if the product matches a tighter pH band.
- Buffer identity escalation (Claims 5-6 and Claim 15) if succinate is used.
- Strength escalation (Claims 7-9 and Claim 15) if the marketed strength fits.
- Formulation compatibility escalation (Claims 10-12 and Claim 15) if isotonicity and NaCl are used.
- Proof pressure via stability (Claims 13-14) when pH and buffer are contested or when multiple formulations exist.
US patent landscape: how this claim set typically clusters around related filings
A formulation set built from:
- acidic pH range control,
- specific buffer identity,
- concentration brackets,
- isotonicity adjustment,
- and stability thresholds
…commonly appears as a “second-wave” IP layer around an earlier composition/active ingredient protection. In US practice, related filings often include:
- continuation or divisional family members with different pH bands or different buffer systems,
- method-of-treatment claims paired with formulation claims,
- and later strengthening amendments that create additional dependent hooks tied to stability outcomes.
However, a complete patent landscape mapping requires the patent’s application family, assignee, priority, filing dates, and the full USPTO citation network. Those data are not present in the claim text provided here. Without that, a defensible landscape cannot be produced.
Key takeaways
- US 10,344,765 is a formulation-rights patent focused on aqueous AMG 416 hydrochloride with pH 2.0 to 5.0 as the core gate (Claim 1).
- The tightest commercial hook is Claim 15, which stacks pH ~3.0 to 3.5, succinate buffer, AMG 416 concentration 2 to 20 mg/mL, and NaCl isotonicity.
- Buffer (succinate), tonicity (NaCl isotonicity), and stability (<10% degradation over 2 years) are key dependent claim levers that can narrow infringement theories and support performance-based arguments.
- For FTO, the decisive question is whether the product sits in pH 2.0 to 5.0 in aqueous AMG 416 hydrochloride. If yes, Claim 1 creates baseline exposure irrespective of succinate/NaCl.
FAQs
-
Does succinate matter for infringement under Claim 1?
No. Succinate is required only for the dependent buffer claims (Claims 5-6, and Claim 15). Claim 1 requires only aqueous solution of AMG 416 hydrochloride with the pH range.
-
What single parameter most directly drives Claim 1 infringement risk?
The formulation pH must fall within 2.0 to 5.0 for the aqueous AMG 416 hydrochloride formulation.
-
If a product uses pH 4.7, does it still fall within the patent?
It can still fall within Claim 1 if pH is within 2.0 to 5.0, but it may avoid narrower dependent pH claims like Claim 3 and Claim 4 depending on the exact pH.
-
Can changing NaCl avoid infringement?
It can avoid dependent claim coverage tied to NaCl identity (Claim 12 and Claim 15) but may not avoid Claim 1 if pH remains within 2.0 to 5.0.
-
How do Claims 13 and 14 affect legal strategy?
They add a performance requirement: the formulation must show <10% degradation after 2 years at 2-8°C and at room temperature.
References
[1] User-provided claim text for US Drug Patent 10,344,765 (claims 1-15).
